Manufacturer of Controlled Substances; Notice of Application; Cayman Chemical Company, 14297 [2014-05493]
Download as PDF
<![CDATA[
14297
Federal Register / Vol. 79, No. 49 / Thursday, March 13, 2014 / Notices
Dated: February 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Johnson Matthey, Inc.
[FR Doc. 2014–05488 Filed 3–12–14; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Cayman Chemical Company
Pursuant to 21 CFR 1301.33(a), this is
notice that on December 6, 2013,
Cayman Chemical Company, 1180 East
Ellsworth Road, Ann Arbor, Michigan
48108, made application by
correspondence to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:
Drug
Schedule
2-(4-bromo-2,5-dimethoxyphenyl)N-(2-methoxybenzyl)
(25B–
NBOMe) (7536).
2-(4-chloro-2,5-dimethoxyphenyl)N-(2-methoxybenzyl)
(25C–
NBOMe) (7537).
2-(4-iodo-2,5-dimethoxyphenyl)-N(2-methoxybenzyl)
(25I–
NBOMe) (7538).
I
I
I
TKELLEY on DSK3SPTVN1PROD with NOTICES
The company plans to manufacture
the listed controlled substances, and
distribute those substances to its
research and forensics customers for
drug testing and analysis.
Any other such applicant, and any
person who is presently registered with
the DEA to manufacture such
substances, may file comments or
objections to the issuance of the
proposed registration pursuant to 21
CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODW), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than May 12, 2014.
Dated: Signed February 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2014–05493 Filed 3–12–14; 8:45 am]
BILLING CODE 4410–09–P
VerDate Mar<15>2010
17:33 Mar 12, 2014
Jkt 232001
By Notice dated November 5, 2013,
and published in the Federal Register
on November 18, 2013, 78 FR 69132,
Johnson Matthey, Inc., Custom
Pharmaceuticals Department, 2003
Nolte Drive, West Deptford, New Jersey
08066–1742, made application by
renewal to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the following
basic classes of controlled substances:
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a),
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: February 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2014–05503 Filed 3–12–14; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Drug
Schedule
Gamma
Hydroxybutyric
Acid
(2010).
Tetrahydrocannabinols (7370) .....
Dihydromorphine (9145) ...............
Difenoxin (9168) ...........................
Propiram (9649) ...........................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Lisdexamfetamine (1205) .............
Methylphenidate (1724) ................
Nabilone (7379) ............................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Diphenoxylate (9170) ...................
Ecgonine (9180) ...........................
Hydrocodone (9193) .....................
Meperidine (9230) ........................
Methadone (9250) ........................
Methadone intermediate (9254) ...
Morphine (9300) ...........................
Thebaine (9333) ...........................
Oxymorphone (9652) ...................
Noroxymorphone (9668) ..............
Alfentanil (9737) ...........................
Remifentanil (9739) ......................
Sufentanil (9740) ..........................
Tapentadol (9780) ........................
Fentanyl (9801) ............................
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for sale to its customers.
No comments or objections have been
received. The DEA has considered the
factors in 21 U.S.C. 823(a), and
determined that the registration of
Johnson Matthey, Inc., to manufacture
the listed basic classes of controlled
substances is consistent with the public
interest at this time. The DEA has
investigated, Johnson Matthey, Inc., to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
PO 00000
Frm 00086
Fmt 4703
Sfmt 4703
Manufacturer of Controlled
Substances; Notice of Registration;
Cedarburg Pharmaceuticals, Inc.
By Notice dated October 16, 2013, and
published in the Federal Register on
October 25, 2013, 78 FR 64017,
Cedarburg Pharmaceuticals, Inc., 870
Badger Circle, Grafton, Wisconsin
53024, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the following basic
classes of controlled substances:
Drug
4-Anilino-N-phenethyl-4-piperidine
(8333).
Remifentanil (9739) ......................
Fentanyl (9801) ............................
Schedule
II
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
No comments or objections have been
received. The DEA has considered the
factors in 21 U.S.C. 823(a), and
determined that the registration of
Cedarburg Pharmaceuticals, Inc. to
manufacture the listed basic classes of
controlled substances is consistent with
the public interest at this time. The DEA
has investigated Cedarburg
Pharmaceuticals, Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823(a)
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
E:\FR\FM\13MRN1.SGM
13MRN1
]]>Agencies
[Federal Register Volume 79, Number 49 (Thursday, March 13, 2014)]
[Notices]
[Page 14297]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-05493]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application;
Cayman Chemical Company
Pursuant to 21 CFR 1301.33(a), this is notice that on December 6,
2013, Cayman Chemical Company, 1180 East Ellsworth Road, Ann Arbor,
Michigan 48108, made application by correspondence to the Drug
Enforcement Administration (DEA) to be registered as a bulk
manufacturer of the following basic classes of controlled substances:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
2-(4-bromo-2,5-dimethoxyphenyl)-N-(2- I
methoxybenzyl) (25B-NBOMe) (7536).
2-(4-chloro-2,5-dimethoxyphenyl)-N-(2- I
methoxybenzyl) (25C-NBOMe) (7537).
2-(4-iodo-2,5-dimethoxyphenyl)-N-(2- I
methoxybenzyl) (25I-NBOMe) (7538).
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances,
and distribute those substances to its research and forensics customers
for drug testing and analysis.
Any other such applicant, and any person who is presently
registered with the DEA to manufacture such substances, may file
comments or objections to the issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODW), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than May 12, 2014.
Dated: Signed February 19, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 2014-05493 Filed 3-12-14; 8:45 am]
BILLING CODE 4410-09-P
